Bert N. La Du

Bert N. La Du's AcademicInfluence.com Rankings

Bert N. La Du

Biology

#11510

World Rank

#14911

Historical Rank

Biochemistry

#1906

World Rank

#2047

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Bert N. La Du Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Bert N. La Du's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. (1995) (1204)
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. (1998) (1187)
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. (1995) (803)
The human serum paraoxonase/arylesterase polymorphism. (1983) (771)
The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. (1996) (681)
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M (2005) (655)
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. (1999) (641)
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. (1991) (594)
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. (1993) (512)
Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. (1998) (464)
Enzymatic metabolism of drugs and other foreign compounds. (1958) (454)
Pharmacogenetics of paraoxonases: a brief review (2004) (418)
Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. (2000) (394)
Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. (1999) (374)
The oxidation of drugs by liver microsomes: on the role of TPNH and oxygen. (1957) (354)
Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation* (2000) (329)
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. (1997) (323)
The nature of the defect in tyrosine metabolism in alcaptonuria. (1958) (310)
The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. (1983) (306)
Current progress on esterases: from molecular structure to function. (2002) (303)
Enzymatic dealkylation of aminopyrine (pyramidon) and other alkylamines. (1955) (233)
Detoxication of drugs and other foreign compounds by liver microsomes. (1955) (232)
DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. (1992) (213)
Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. (1999) (195)
On the physiological role(s) of the paraoxonases. (1999) (186)
Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. (1989) (183)
Mouse Macrophage Paraoxonase 2 Activity Is Increased Whereas Cellular Paraoxonase 3 Activity Is Decreased Under Oxidative Stress (2003) (168)
Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. (1990) (150)
Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. (1980) (147)
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. (2003) (145)
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. (1995) (143)
Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2 (1993) (139)
A chemical method for the determination of free choline in plasma. (1953) (132)
Comparison of purified human and rabbit serum paraoxonases. (1995) (125)
Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. (1998) (122)
Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. (1991) (121)
Studies on human serum paraoxonase/arylesterase. (1993) (119)
Interchain disulfide bonds and subunit organization in human serum cholinesterase. (1979) (117)
Comparison of atypical and usual human serum cholinesterase. Purification, number of active sites, substrate affinity, and turnover number. (1978) (116)
Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. (1996) (103)
Location of disulfide bonds within the sequence of human serum cholinesterase. (1987) (99)
An enzymatic spectrophotometric method for the determination of phenylalanine in blood. (1960) (94)
Brain cDNA clone for human cholinesterase. (1987) (90)
High density associated enzymes: their role in vascular biology. (1998) (88)
Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. (2002) (81)
Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. (1990) (77)
DNA mutations associated with the human butyrylcholinesterase J-variant. (1992) (75)
Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT----GGAG). (1990) (67)
Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. (1982) (62)
The enzymatic defect in histidinemia. (1962) (60)
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. (2001) (57)
Identification of two different point mutations associated with the fluoride-resistant phenotype for human butyrylcholinesterase. (1992) (55)
An enzymatic spectrophotometric method for the determination of homogentisic acid in plasma and urine. (1961) (53)
THE ROLE OF ASCORBIC ACID IN TYROSINE METABOLISM (1961) (48)
Estrogen esters as substrates for human paraoxonases. (2007) (44)
PON1 and oxidative stress in human sepsis and an animal model of sepsis. (2010) (43)
Use of the polymerase chain reaction for homology probing of butyrylcholinesterase from several vertebrates. (1991) (43)
The genetic mapping and gene structure of mouse paraoxonase/arylesterase. (1995) (42)
Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. (2003) (42)
Studies on ochronosis. II. Studies on benzoquinoneacetic acid, a probale intermediate in the connective tissue pigmentation of alcaptonuria. (1962) (39)
Baculovirus-mediated expression and purification of human serum paraoxonase 1A. (2001) (38)
Tyrosyluria resulting from inhibition of p-hydroxyphenylpyruvic acid oxidase in vitamin C-deficient guinea pigs. (1960) (37)
Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies. (1981) (37)
Characterization of a soluble mouse liver enzyme capable of hydrolyzing diisopropyl phosphorofluoridate. (1999) (37)
Assessment of cassia gum. (1997) (37)
Hydrolysis of methylprednisolone acetate by human serum cholinesterase. (1982) (34)
The tyrosine oxidation system of liver. I. Extracts of rat liver acetone powder. (1951) (33)
The polymorphic paraoxonase/arylesterase isozymes of human serum. (1984) (33)
An improved method for phenotyping individuals for the human serum paraoxonase arylesterase polymorphism. (1986) (29)
Two polymorphisms in the non-coding regions of the BCHE gene. (1990) (28)
Structural basis of the butyrylcholinesterase H-variant segregating in two Danish families. (1992) (28)
Ascorbic acid and the oxidation of tyrosine. (1953) (28)
The tyrosine oxidation system of liver. II. Oxidation of p-hydroxyphenylpyruvic acid to homogentisic acid. (1955) (27)
Alcaptonuria; clinical staff conference at the National Institutes of Health. (1957) (24)
Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. (2001) (24)
Nonspecificity of tyrosine transaminase: an explanation for the simultaneous induction of tyrosine, phenylalanine, and tryptophan transaminase activities in rat liver. (1962) (23)
The human serum paraoxonase/arylesterase polymorphism. (1988) (22)
Evaluation of health aspects of GRAS food ingredients: lessons learned and questions unanswered. (1977) (21)
Studies on the defect in tyrosine metabolism in scorbutic guinea pigs. (1960) (21)
Prolonged response to succinylcholine: a new variant of plasma cholinesterase that is identified as normal by traditional phenotyping methods. (1995) (21)
Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase. (1997) (19)
Paraoxon hydrolysis vs. covalent binding in the elimination of paraoxon in the rabbit. (1985) (19)
Recommended nomenclature system for the paraoxonases. (1999) (18)
Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase. (1999) (17)
Studies on ochronosis. I. The distribution of homogentisic acid in guinea pigs. (1962) (17)
Phenylalanine metabolism and "phenylketonuria" in dilute-lethal mice. (1966) (17)
Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase. (1999) (16)
The enzymatic deficiency in tyrosinemia. (1967) (16)
Alcaptonuria and ochronotic arthritis. (1991) (16)
Molecular biology of human serum cholinesterase. (1986) (13)
A rapid screening test for atypical serum-cholinesterase. (1966) (12)
The tyrosine oxidation system of liver. IV. Studies on the inhibition of p-hydroxyphenylpyruvic acid oxidase by excess substrate. (1959) (12)
A mathematical model for evaluating the reaction of paraoxon with human serum cholinesterase and with polymorphic forms of paraoxonase. (1984) (11)
Plasma esterase activity and the metabolism of drugs with ester groups. (1971) (11)
The determination of the solubility of cyclopropane in fats and oils with the use of the Warburg apparatus. (1952) (10)
The tyrosine oxidation system of liver. III. Further studies on the oxidation of p-hydroxyphenylpyruvic acid. (1956) (10)
Are we ready to try to cure alkaptonuria? (1998) (10)
Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease. (2003) (9)
Analysis of the serum paraoxonase/arylesterase polymorphism in some Sudanese families. (1986) (8)
Is paraoxonase-3 another hdl-associated protein protective against atherosclerosis? (2001) (8)
The paraoxonase polymorphism in a Saudi Arabian population. (1993) (8)
Evaluation of the safety of sodium pectate as a food ingredient. (1996) (7)
Alcaptonuria and ochronotic arthritis. (1958) (7)
The butyrylcholinesterase gene (BCHE) at 3q26.2 shows two RFLPs. (1991) (7)
Structural and functional diversity of paraoxonases (1996) (7)
Pharmacogenetics: defective enzymes in relation to reactions to drugs. (1972) (7)
Altered drug response in hereditary disease. (1965) (6)
Genetic regulation of plasma cholinesterase in man. (1970) (6)
The effect of coenzyme Q-10 on tyrosine metabolism in guinea pigs. (1962) (5)
Toxicity of Some Synthetic Pteridines in Rats.∗ (1950) (4)
The effect of folic acid on tyrosine metabolism in guinea pigs. (1962) (4)
Butyrylcholinesterase variants and the new methods of molecular biology. (1995) (4)
Determination of histidine alpha-deaminase in human stratum corneum and its absence in histidinaemia. (1963) (4)
[Distribution of different phenotypes of paraoxonase in a French population]. (1986) (2)
The importance of early diagnosis and treatment of phenylketonuria. (1959) (2)
The role of genetics in idiosyncratic reactions or adverse reactions to foods. (1990) (2)
Increased plasma cholinesterase activity and mivacurium resistance: report of a family. (1999) (2)
Detection of human DNA mutations with nonradioactive, allele-specific oligonucleotide probes. (1992) (2)
Isoniazid and psuedocholinesterase polymorphisms. (1972) (1)
Identification of human serum cholinesterase variants using the polymerase chain reaction amplification technique. (1989) (1)
Histidinemia. Current status. (1967) (1)
Commentary: drug metabolism and pharmacogenetics. (1983) (1)
Genetic determimants in drug action. (1972) (0)
Effects of GRAS substances on pharmacologic effects of drugs. (1977) (0)

This paper list is powered by the following services:

Bert N. La Du's Academic­Influence.com Rankings

Why Is Bert N. La Du Influential?

Bert N. La Du's Published Works

Published Works

Bert N. La Du's AcademicInfluence.com Rankings